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ABSTRACT
Blood transfusion is a life-saving component of health care systems. Nevertheless, it 
can also be a quick and easy method of exposing patients to risks, particularly the 
transmission of infectious agents to recipients. Despite substantial improvements in 
the safety of transfusion services worldwide, the presence of paid and replacement 
blood donors are still of cause concern for ensuring sustainable safe blood donations. 
Although the Eastern Mediterranean region consists of a heterogeneous group of 
countries that vary in their levels of development, they all share common concerns 
regarding blood safety. In the region, concerns regarding the spread of Hepatitis B and 
C through blood transfusion continue to exist. Therefore, there is an urgent need for 
further improvements in both organization and safety measures of blood transfusion 
activities in the region. Although establishing a centralized blood transfusion system 
might not be achievable in the short term in some of the countries in the region, the 
implementation of centralized test kit procurement, data collection, and donation 
testing could be considered feasible approaches.
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  Implication for health policy/practice/research/medical education:
Blood transfusion is still an essential component of modern health care. However despite improvement in availability of the blood 
and blood components in countries of Eastern Mediterranean Region there still substantial concerns regarding both availability and 
safety of blood and blood components in some of these countries which obviously could jeopardize patient’s safety.  
  Please cite this paper as: 
Cheraghali AM. Blood safety concerns in the Eastern Mediterranean region. Hepat Mon. 2011;11(6):422-6.
1. Background
Presently, blood transfusion is an essential component 
of modern health care that saves millions of lives each 
year, and it will continue to be so for many years to come. 
Every  second,  someone  in  the  world  needs  blood  for 
surgery, trauma, severe anemia, or complications from 
pregnancy.  According  to  a  World  Health  Organization 
(WHO) estimate, each year over 100 million people sustain 
injuries and more than five million die from violence and 
injury. Annually, worldwide, more than 536,000 women 
die during pregnancy or childbirth; 99% of these cases 
are  in  developing  countries,  and  most  mortalities  are 
due to bleeding (1). Therefore, the availability of timely 
and  safe  blood  transfusions  in  health  care  facilities 
providing  emergency  obstetric  care  can  entail  the 
difference between life and death. Although in developed 
countries, transfusion of blood and blood components is 
mostly used to support advanced medical and surgical 
procedures, in resource-limited countries, the majority of 
blood and its components are used for the management 
of  obstetric  emergencies  and  children  suffering  from 
severe anemia. Blood transfusions can also be a quick 
and easy way of exposing risks, such as transmission of 
infectious agents like HIV, HBV, HCV, and malaria to the 
recipients. Despite considerable improvements in blood 
transfusion  safety  measures  in  developing  countries, Hepat Mon. 2011;11(6):422-426
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blood transfusion still accounts for a substantial portion 
of  HIV  transmissions  in  developing  countries.  Known 
and emerging threats to blood safety and the balance 
between  the  impact  of  measures  to  contain  these 
threats, and the adequacy and accessibility of blood and 
blood  components  require  national  coordination  and 
planning. Every nation should meet its requirements for 
blood and blood products and ensure that blood supplies 
are  practically  free  from  life-threatening  transfusion-
transmissible infections (TTIs).
Unfortunately, millions of patients living in developing 
countries  do  not  have  timely  access  to  safe  blood. 
Although more than 80% of the world’s population lives 
in the developing world, less than 45% of over 100 million 
units of blood donated globally are collected in these 
countries. The average number of blood donations per 
1,000 persons is 10 times higher in high-income countries 
than  low-income  countries.  An  inadequate  stock  of 
blood  usually  forces  health  providers  in  low-income 
countries to turn to unsafe replacements or paid donors, 
thus  increasing  the  risk  of  using  with  questionable 
safety.  Lack  of  qualified  organizational  practices 
such  as  fragmentation  and  low  efficiency  of  blood 
services’ operations, as well as lack of tangible political 
commitment  and  support,  are  the  main  challenges 
in  developing  countries  regarding  blood  safety.  These 
usually lead to difficulties in ensuring the sustainability 
of blood services. In order to improve blood safety and 
the  availability  of  blood  components,  the  WHO  has 
proposed a five-tiered strategy for the establishment of a 
national blood transfusion policy and service. The main 
components of this strategy are as follows (2):
  The  establishment  of  well-organized,  nationally 
coordinated blood transfusion;
  The  collection  of  blood  from  voluntary  non-
remunerated blood donors;
  Quality-assured  testing  for  TTIs  and  compatibility 
testing;
The safe and appropriate use of blood;
  Quality  systems  covering  the  entire  transfusion 
process.
Sadly,  despite  a  markedly  inadequate  blood  supply 
in many countries, especially in the developing world, 
even  when  simpler  and  less  expensive  interventions 
with equal benefit are available, the inappropriate use 
of blood transfusions will push the availability of the 
blood  components  to  its  limit.  Citizens  in  developing 
countries might not even have universal access to blood 
transfusions.  In  these  countries,  the  development  of 
blood transfusion services has been largely restricted to 
major cities, and people living in rural and remote areas 
mostly lack access to safe blood.
2. Global status of transfusion safety
The following are the findings of a survey published by 
the WHO in 2010 (3) on the basis of data collected from 
173 countries that received 93 million blood donations:
41 countries were unable to screen all blood donations 
for  one  or  more  of  the  following  TTIs,  including  HIV, 
HBV, HCV, and syphilis. Only 47% of blood donations in 
developing countries are screened following basic quality 
assurance procedures. Of the 93 million donations, 50% 
were collected in developed countries, home to 16% of 
the world’s population.
It is estimated that donations from 1% of the population 
is generally the minimum needed to meet a nation’s most 
basic requirements for blood. The average donation rate is 
3% in developed countries, 0.75% in transitional countries, 
and an average of 0.37% in developing countries. 
Although  56  countries  reported  more  than  a  10% 
increase  in  voluntary  unpaid  blood  donations,  15 
countries  reported  more  than  a  10%  decrease  in  this 
figure compared to the previous year’s figure.
The availability of blood with compromised safety might 
expose recipients to avoidable life-threatening risks. The 
transmission of viral and other infections like syphilis 
and malaria are among the most important risks when 
receiving tainted blood. However, there are also concerns 
regarding the transmission of emerging diseases through 
blood transfusion. An unsafe blood supply represents the 
major contributor of the transmission of HCV, especially 
in many developing countries (4). It is also estimated 
that blood transfusion may account for up to 15% of HIV 
transmissions in developing countries (5). To improve 
blood safety, the aim should be to reduce the number of 
transfusions to the minimum whenever feasible and to 
use blood substitutes wherever available.
3. Status of blood safety in the region
The  Eastern  Mediterranean  region  consists  of  a 
heterogeneous group of countries with various levels of 
development. However, they all share common concerns 
regarding blood safety. In the 1990s, blood transfusions 
was  reported  to  be  one  of  the  main  causes  of  HIV 
contamination in the Middle East (6). A cumulative total 
of 3,745 AIDS cases were reported from the countries of 
the region through the end of 1995. Information about 
the mode of transmission was available in 3,461 cases 
(92.4%). Of that percentage, 368 (10.6%) cases were due 
to the receipt of blood or blood products, the largest 
numbers of which were reported in Iran, Morocco, Saudi 
Arabia, Egypt, and Iraq. However, it was later proven that 
the majority of the HIV cases in Iranian patients who 
received  blood  products  were  attributed  to  imported 
concentrated coagulation factors (7). Nonetheless, owing 
to  improvements  in  transfusion  safety  in  the  region, 
blood transfusion is no longer the main route of HIV 
transmission.
Despite  recent  improvements  in  the  safety  of 
transfusion services in the region, concerns regarding 
the role of blood transfusion in the spread of hepatitis B 
and C in the region continue to exist (8). Therefore, WHO 
has urged regional member states to ensure transfusion 
safety by promoting safe blood donation, strengthening Hepat Mon. 2011;11(6):422-426
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national regulatory activities related to quality assurance, 
and assuring the safety of blood products (8). Although 
there is established data confirming that the prevalence 
of HIV, hepatitis viruses, and other TTIs are lowest among 
unpaid blood donors who give blood voluntarily, several 
countries in the region still rely heavily on remunerated 
donors and/or replacement donors. Despite the presence 
of  a  centralized  blood  transfusion  service  in  some 
countries of the region, such as Iran, several countries 
show  a  high  degree  of  fragmented  blood  transfusion 
services. Inappropriate clinical use of blood and blood 
products is also a major regional problem (1).
A few number of English published data is available that 
describes blood safety statuses in the region. This type of 
data is even scarcer with regard to Arab countries of the 
Persian Gulf coasts. According to a published survey from 
17 Arab countries, 14 had thus far formulated a national 
policy but only nine had national regulation. In 2004, a 
total of 2,400,000 units of blood were collected in these 17 
countries. The proportion of blood collected on the basis 
of  voluntary  blood  donation  in  these  countries  varies 
drastically and is reported to be between 3% and 100%. 
Donation  rates  vary  from  0.2%  (Syria)  to  2.7%  (Kuwait) 
(9).  However,  all  this  donated  blood  is  tested  against 
hepatitis  B  and  C  and  HIV  in  these  countries.  Multi-
transfused  patients,  including  thalassemia  patients, 
are among the most vulnerable to TTIs. Therefore, the 
prevalence of infectious agents in this group of patients 
could be considered an indirect index of blood safety. 
The prevalence of HCV infection in thalassemia patients 
in the Eastern Mediterranean region has been recently 
reviewed (10).
Although up to 80% of adult thalassemia patients are 
infected  with  HCV  in  the  world,  there  is  substantial 
variation among the countries in the region. For example, 
in Iran, HCV infection rates range from 2% to 32% and in 
Saudi Arabia, from 33% to 93%. In Kuwait and Jordan, all 
the  HCV-infected  thalassemia  cases  were  transfused 
before the onset of blood donor screening. Among the 
major  countries  in  the  region,  Iran  showed  the  least 
seroprevalence  of  HCV  infection  among  thalassemia 
patients.  This  underscores  the  more  advanced  blood 
safety in this country. However, in this regard, there is no 
data from most of the countries in the region (10). In Egypt, 
sexual contact is the main cause (71%) of HIV transmission. 
However, cumulatively and until 2009, blood and blood 
products were identified as the cause of infection in 5% 
of the cases (11). To prevent HIV transmission through 
blood and blood products, a blood safety policy applies 
to all blood banks in Egypt, which includes the screening 
of donated blood for HBV, HCV, HIV, and syphilis. From 
2008 and 2009, 52 HIV-positive blood bags were detected 
and  discarded.  In  2009,  a  total  number  of  1,280,000 
blood  units  were  screened  and  44  HIV-positive  blood 
bags were detected and discarded (11). An analysis of data 
from 211,772 blood samples collected from 2000 to 2008 
in Egypt (12) has shown that the overall HBsAg and anti-
HCV prevalence were 1.65% and 9.02%, respectively. Anti-
HCV and HBsAg prevalence has dropped from 11.06% (in 
2000) to 6.3% (in 2008) and from 1.24% (in 2000) to 1.17% 
(in 2008), respectively. The prevalence of anti-HCV and 
HBsAg was significantly higher among males donors (10% 
and 1.74%, respectively) compared with females (3% and 
1.07%, respectively). It was also reported that there was 
a significantly higher occurrence of both anti-HCV and 
HBsAg prevalence among donors from rural area (11.3% 
and 2.27%, respectively) compared with urban donors (12). 
Kuwait’s central blood bank is the only public supplier of 
blood and blood components in Kuwait that performs 
blood  and  blood  component  collection,  processing, 
testing,  distribution,  and  transfusion  services  for  all 
governmental and private hospitals in the country. As a 
reflection of the country’s multinational residences, over 
the past decades only 40–43% of blood donors in Kuwait 
were Kuwaiti nationals. On the basis of a study conducted 
in 2002 among 26,874 blood donors to Kuwait’s central 
blood bank, 51.2% were Kuwaiti nationals and 48.8% were 
non-Kuwaiti Arabs. However, only 15.3% of donations were 
volunteers, while 84.7% were replacement donors (13).
The  prevalence  of  anti-HCV  among  Kuwaiti  national 
and  non-Kuwaiti  Arab  first-time  donors  was  0.8  and 
5.4%, respectively, whereas the prevalence of HBsAg was 
1.1 and 3.5%, respectively. Among the first-time donors, 
13.7 percent were positive for the presence of anti-HBs 
(13).  These  figures  show  that  the  heterogeneity  of  the 
population living in Kuwait, and the primary reliance 
on replacement blood donors, might have a significant 
impact on the prevalence of hepatitis infection among 
blood donors. In Iran, blood transfusion is an integral 
part of the national health system, and blood donation is 
voluntary and non-remunerated. In 1974 and following the 
establishment of the Iran Blood Transfusion Organization 
(IBTO),  all  blood  transfusion  activities—from  donor 
recruitment  to  production  of  blood  components  and 
delivery of blood and blood products—were centralized. 
In order to meet the country’s demand in 2010, the IBTO 
collected more than 1.8 million units of blood for the 
country’s  population  of  74  million.  Continued  donor 
recruitment efforts in Iran have resulted in a significant 
increase in blood donation rates during the past decade, 
excluding “family replacement” donations, and achieved 
a 100% voluntary non-remunerated blood donation rate 
in 2007 (14-16).
The prevalence of HBsAg has been evaluated in blood 
donations in Iran over the period from 1998–2007 (17). A 
total of 14,599,783 donations were collected during these 
10 years. The overall HBsAg prevalence rates declined from 
1.79% in 1998 to 0.41% in 2007 as a result of improvements 
in  donor  recruitment  and  selection,  implementation 
of  automation  in  transfusion  services,  and  a  possibly 
decreasing  HBV  infection  prevalence  in  the  general 
population.  A  separate  report  has  also  examined  the 
results from the viral screening of 6,499,851 donations 
from 2004 through 2007 for HBV, HCV, HIV, and syphilis 
(18,19). The overall prevalence of these viral markers was 
0.56% for HBV, 0.004% for HIV, and 0.13% for HCV. There Hepat Mon. 2011;11(6):422-426
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was  a  significant  decrease  in  HBsAg  prevalence  from 
0.73%  in  2004  to  0.41%  in  2007.  Despite  an  increasing 
HIV  prevalence  in  the  general  population  of  Iran,  the 
prevalence  of  HIV  decreased  from  0.005%  in  2004  to 
0.004% in 2007. HCV prevalence showed a slight decline 
in blood donations from 0.14% in 2005 to 0.12% in 2007.
The  situation  in  Pakistan  with  regard  to  blood 
transfusion  has  remained  far  from  satisfactory  over 
the  years  (20-23).  There  is  extreme  fragmentation  and 
rampant commercialism with questionable transfusion 
practice quality in the majority of blood establishments 
throughout the country. The blood transfusion services in 
Pakistan are mostly hospital-based, and majority of blood 
donors are usually first-time replacement donors or paid 
and directed donors. About 75% of blood donations in 
Pakistan come from replacement donors, and around 15% 
of the blood is still donated by professional donors. Only 
10% of blood donors in Pakistan make voluntary unpaid 
donations.  It  seems  the  cultural  and  socioeconomic 
factors are associated with a reluctance to donate blood 
at all, especially without reward. The annual estimated 
requirement of blood is approximately 1.5 million units, 
with 40% of the demand being met by the public sector. 
Although  there  is  about  a  40%  shortage  of  blood  and 
blood components in this country, about 85% of blood 
used as whole blood products (20).
In Pakistan, crude low-sensitivity kits, available at very 
low  prices,  are  being  used  for  screening.  Commercial 
blood  donors  with  infections  like  HIV,  HCV,  and  HBV 
are  not  stringently  screened  before  a  blood  donation. 
Published  reports  indicate  discouraging  trends  in 
appropriate  screenings  of  potential  donors  for  viral 
infections, unsafe sexual behavior, and drug abuse (22). 
Data on the serologic testing of blood donors for HBV, 
HCV, HIV, and syphilis in a 10-year period (1996–2005) in 
Lahore  has  been  reviewed.  The  frequency  of  serologic 
markers ranged from 1.46–2.99% for HBV, with a downward 
trend over time: 3.01–4.99% for HCV, 0–0.06% for HIV, and 
0.19–0.57% for syphilis (23). However, volunteer donors 
(6.98% of all the donors) had the lowest seroprevalence 
for the diseases.
The statuses of blood transfusion services in Afghanistan 
have also been reviewed recently (24). Owing to the lack 
of appropriate infrastructure and resources, the national 
blood supply system is damaged and heavily disrupted. 
Afghanistan, with an estimated population of 30 million, 
needs at least 300,000 units of blood. Presently, more 
than 95% of blood donation in Afghanistan comes from 
family replacements, which are often paid by the patient’s 
family, and less than 5% are from voluntary donors.
4. Conclusion
There is a consensus that a centralized blood transfusion 
service has the ability to improve the availability of safe 
blood and blood components. Although this might be 
a far-reaching goal in some countries of the region, the 
implementation  of  centralized  test  kits,  procurement 
and  donation  testing  could  be  considered  feasible 
approaches. Usually, a fragmented blood supply system 
with  varying  technical  standards  and  no  central 
supervision  might  disrupt  safety  measures.  Published 
data regarding blood safety in the region is scarce and 
primarily consists of either one or a limited number of 
blood centers with a small number of blood samples. 
Therefore, it would be difficult to extrapolate results from 
such studies to the national level. The establishment of a 
data collection center at a national level, even in countries 
without centralized blood transfusion services, would be 
essential for analyzing data regarding the current blood 
safety status and future planning in regional countries.
Collecting  blood  only  from  voluntary  donors  might 
not  be  an  attainable  goal,  at  least  in  the  short-term, 
for  many  developing  countries  (25),  including  some 
countries in the region. Therefore, it seems that national 
policymakers  in  these  countries,  while  establishing  a 
long-term plan to attain 100% voluntary blood donations, 
should  implement  a  plan  to  wisely  use  replacement 
donors for providing safe blood to patients in need of 
blood and blood products. Since 2004, Iran, in a unique 
experience  in  the  region,  has  established  a  long-term 
self-sufficiency plan for plasma-derived medicines using 
plasma recovered from donated blood to the national 
blood  centers.  The  implemented  plasma  contract 
fractionation activity has remarkably improved quality 
assurance systems in Iran’s national transfusion service, 
which  ultimately  has  improved  both  national  blood 
safety and the affordability of plasma-derived medicines 
(7, 26). There is strong evidence that this approach could 
be emulated by other countries in the region.
In conclusion, the people of the Eastern Mediterranean 
region, regardless of their wealth or social status, need 
safe blood transfusions in situations where transfusion 
is  a  life-saving  procedure.  Therefore,  equity  in  the 
availability of blood for any citizen could be considered a 
development index in every country’s health sector.
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